Indaptus Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 15.42 million compared to USD 14.32 million a year ago. Basic loss per share from continuing operations was USD 1.83 compared to USD 1.73 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 USD | -3.21% | -10.59% | +19.89% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.89% | 18.02M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INDP Stock
- News Indaptus Therapeutics, Inc.
- Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023